1. DISEASE CHARACTERISTICS 1.1 Name of the disease (synonyms) See Table 1 
Mutational spectrum:
(Please note the EJHG instructions for authors http://mts-ejhg.nature. com/cgi-bin/main.plex?form_type=display_auth_instructions regarding sequence variants and genetic databases.) All types of variants have been reported 3 (missense, nonsense, splice site, small and large deletions/insertions). Many variants are listed in the Human Gene Mutation Database (http://www.hgmd.org/) and in ClinVar. 4 The 'Locus Specific Mutation Database' from HGVS gives an overview of gene-specific mutation databases, for example, FBN1, FBN2, TGFBR1, TGFBR2, ACTA2, SMAD3, MYH11 and MYLK variants are also registered in The Universal Mutation Database (www.umd.be). In general, there are no frequent disease-causing mutations or hot spots for disease-causing mutations in the vast majority of the genes. Causative mutations are distributed throughout the genes. However, some trends are observed for disease-causing mutations in specific genes (for example, exons encoding intracellular domains of TGFBR1 and TGFBR2, and recurrent mutations in PRKG1).
SNPs or rare variants are listed in the dbSNP Database (http://www. ncbi.nlm.nih.gov/snp/), the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/) and in the Exome Aggregation Consortium (http://exac.broadinstitute.org/). Please note that the above-mentioned databases include pathogenic mutations.
Analytical validation
Sequencing of both DNA strands. Disease-causing mutations should be confirmed using genomic DNA from a new extraction. Causative mutations found with next-generation sequencing should be verified using Sanger sequencing or other specific molecular methods (eg, PCR digest); for further details, see the Eurogentest Guideline. 2 Note: the nomenclature of diseases associated with thoracic aortic aneurysm is in part controversial. 15, 16 This CUGC does not attempt to resolve these controversies. In this table, both OMIM and Orpha numbers are given together with their alternative disease designations in the first column. a ATS is used in OMIM as a symbol for both conditions. 
TEST CHARACTERISTICS

if tested by conventional Sanger sequencing
Less than 100%. The proportion is likely o100%, because primers may be localized on sequences containing SNPs or rare variants, which results in a preferential amplification of one allele (allele drop out). A supplementary deletion/duplication diagnostic test should be performed for genes with a known proportion of large genomic deletions/ duplications.
if tested by next-generation sequencing
Less than 100%.
The proportion is likely o100%, because there might be diseasecausing mutations in regions that could not be enriched and/or sequenced by NGS due to suboptimal coverage of some regions of interest with this technology but depending on NGS strategy. If amplicon-based enrichment strategies are being used, primers may be localized on SNPs or rare variants, which results in a preferential amplification of one allele. In patients with a highly suggestive phenotype in whom initial testing for specific gene alterations proves negative, a supplementary deletion/duplication diagnostic test should be performed for genes with a known proportion of large genomic deletions/duplications.
Analytical specificity (proportion of negative tests if the genotype is not present)
if tested by conventional Sanger sequencing
Nearly 100%. False positives may at the most arise due to misinterpretation of rare polymorphic variants.
if tested by next-generation sequencing
Less than 100%. The risk of false positives due to misinterpretation of rare polymorphic variants may even be higher compared with Sanger sequencing because of the greater number of analysed genes.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
if tested by conventional Sanger sequencing
In about 20% of patients presenting with familial AAT, a diseasecausing mutation is found 5 (eg, ACTA2: 4-14%, TGFBR2: 4%, SMAD3: 2%, TGFBR1: 1%, MYH11: 1%, MYLK: 1%, TGFB2, MAT2A, PRKG1, MFAP5).
In syndromic forms of heritable thoracic aortic aneurysm clinical sensitivity is highly dependent on fulfillment of specific clinical criteria for a given entity.
if tested by next-generation sequencing
See 2.3.1.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case.
if tested by conventional Sanger sequencing
Unknown.
if tested by Next-generation sequencing
See 2.4.1.
Positive clinical predictive value (life time risk to develop the disease if the test is positive)
Dependent on clinical subtype, typically 450%.
Negative clinical predictive value (Probability not to develop the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity must need to be considered.
Index case in that family had been tested and a causative mutation identified:
Nearly 100%. If the non-affected relative is not carrier of an identified disease-causing mutation, he or she has no increased risk, except a small risk related to the prevalence of the disease in the general population.
Index case in that family had not been tested or no causative mutation identified:
Up to 19% of patients with TAAD without a known genetic syndrome have a first-degree relative with TAAD. 6 In syndromic forms of heritable thoracic aortic aneurysm, the negative clinical predictive value corresponds to the detection rate in the known genes mutated in the different diseases. 7 
CLINICAL UTILITY
3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.8 'A' was marked) 3.1.1 Can a diagnosis be made other than through a genetic test? No □ (continue with 3.1.4) Yes ⊠ Clinically ⊠ Imaging ⊠ Endoscopy □ Biochemistry □ Electrophysiology □ Other (
IF APPLICABLE, FURTHER CONSEQUENCES OF TESTING
Please assume that the result of a genetic test has no immediate medical consequences. Is there any evidence that a genetic test is nevertheless useful for the patient or his/her relatives? (Please describe).
The genetic diagnostics contributes substantially to the classification of a heritable thoracic aortic aneurysm to a syndromic or nonsyndromic entity. 14 Genetic testing gives insight to inheritance pattern and allows reasonable genetic counseling. If a causative mutation is identified in a gene also responsible for a syndromic form of TAAD, further clinical investigations regarding symptoms of this specific syndrome should be performed. In some cases it might be justified to start medical treatment at an earlier stage.
